The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M05 | Drugs for treatment of bone diseases | |
3
|
M05B | Drugs affecting bone structure and mineralization | |
4
|
M05BX | Other drugs affecting bone structure and mineralization | |
5
|
M05BX06 |
| Active Ingredient |
|---|
|
Romosozumab is a humanized monoclonal antibody (IgG2) that binds and inhibits sclerostin, thereby increasing bone formation due to the activation of bone lining cells, increasing bone matrix production by osteoblasts, and recruitment of osteoprogenitor cells. Additionally, romosozumab results in changes to expression of osteoclast mediators, thereby decreasing bone resorption. |
| Document | Type | Information Source | |
|---|---|---|---|
| EVENITY Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| EVENITY Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.